Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis
Phase 2
Terminated
- Conditions
- Head and Neck CancerBreast Cancer
- Registration Number
- NCT01701466
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Brief Summary
The purpose of this study is to determine whether NeoVIDERM is effective at preventing radiation dermatitis in patients receiving external beam radiation therapy to the head and neck or breast areas.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Maximum skin toxicity 7 weeks post beginning of radiation treatments The objective of this study is to determine the occurrence and degree of acute skin toxicity in patients receiving radical radiation therapy with preventive application of neoVIDERM compared to patients treated with institutional standard skin care.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Neoviderm Skin Emulsion utilize to prevent radiation-induced skin damage in head and neck or breast cancer patients?
How does Neoviderm Skin Emulsion compare to standard-of-care skin care products in preventing radiation dermatitis severity and incidence?
Are there specific biomarkers that could identify patients most likely to benefit from Neoviderm Skin Emulsion in radiation therapy?
What adverse events are associated with Neoviderm Skin Emulsion use during external beam radiation therapy for head and neck or breast cancers?
What are related compounds or combination therapies being explored for radiation dermatitis prevention alongside Neoviderm Skin Emulsion?
Trial Locations
- Locations (1)
Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Jewish General Hospital🇨🇦Montreal, Quebec, Canada